Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Role of versican, hyaluronan and CD44 in ovarian cancer metastasis Ween MP; Oehler MK; Ricciardelli CInt J Mol Sci 2011[Jan]; 12 (2): 1009-29There is increasing evidence to suggest that extracellular matrix (ECM) components play an active role in tumor progression and are an important determinant for the growth and progression of solid tumors. Tumor cells interfere with the normal programming of ECM biosynthesis and can extensively modify the structure and composition of the matrix. In ovarian cancer alterations in the extracellular environment are critical for tumor initiation and progression and intra-peritoneal dissemination. ECM molecules including versican and hyaluronan (HA) which interacts with the HA receptor, CD44, have been shown to play critical roles in ovarian cancer metastasis. This review focuses on versican, HA, and CD44 and their potential as therapeutic targets for ovarian cancer.|Antineoplastic Agents/therapeutic use[MESH]|Carcinoma/drug therapy/*metabolism/pathology/*secondary[MESH]|Female[MESH]|Humans[MESH]|Hyaluronan Receptors/genetics/*metabolism[MESH]|Hyaluronic Acid/*metabolism[MESH]|Ovarian Neoplasms/drug therapy/*metabolism/pathology[MESH]|Paclitaxel/therapeutic use[MESH]|Peritoneal Neoplasms/drug therapy/metabolism/*secondary[MESH]|Versicans/genetics/*metabolism[MESH] |